Effectiveness of amantadine and memantine in catatonia: A retrospective cohort study

Background: Catatonia is a neuropsychiatric syndrome involving motor, behavioral, cognitive, and affective dysfunction that is associated with substantial morbidity and mortality. While benzodiazepines and electroconvulsive therapy (ECT) are first-line treatments for catatonia, alternative pharmacologic options are often used when response is inadequate or ECT is unavailable. N-methyl-D-aspartate receptor antagonists, particularly amantadine and memantine, have been used as second-line agents, though evidence remains limited to case reports and small series. Objective: To evaluate the effectiveness of amantadine and memantine in hospitalized adults with catatonia by assessing changes in symptom severity measured by the Bush-Francis Catatonia Rating Scale (BFCRS). We hypothesized that these agents, when used alongside standard treatments, would generate symptom improvement. Methods: A retrospective study of adults hospitalized at Massachusetts General Hospital from 2016 to 2024 was conducted. Patients hospitalized with a diagnosis of catatonia who were treated with memantine or amantadine were identified from clinical records. Catatonia severity was measured using clinically documented BFCRS scores. Pre-post BFCRS changes were analyzed using Wilcoxon signed-rank tests, with planned sensitivity analyses. Results: Fifty-seven patients received amantadine or memantine for catatonia, mostly as adjunctive treatment. One week (±2 days) after initiation, BFCRS total scores decreased by a mean of 4.9 points ( p < 0.001, r = 0.61). Results remained significant when excluding patients who received ECT during the first week of amantadine or memantine treatment ( n = 48; mean change 5.0, p < 0.001) and those with ⩾50% lorazepam-equivalent dose increases ( n = 39; mean change 4.6, p < 0.001). Conclusion: This represents the largest cohort treated with amantadine or memantine for catatonia. Findings suggest significant symptom reduction, supporting their potential role as an adjunctive option. Prospective studies are needed to clarify predictors of response and comparative effectiveness.

Authors

Institutions

Publication Details

Journal
Journal of Psychopharmacology
Published
2026-10-27
DOI
https://doi.org/10.1177/02698811261495551
Primary Topic
Electroconvulsive Therapy Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of amantadine and memantine in catatonia: A retrospective cohort study

James Luccarelli, Scott Richard Beach, Gregory L. Fricchione, Nathan C. Praschan et al.
Journal of Psychopharmacology
Electroconvulsive Therapy Studies
article

Effectiveness of amantadine and memantine in catatonia: A retrospective cohort study

James Luccarelli, Scott Richard Beach, Gregory L. Fricchione, Nathan C. Praschan, Laura Duque, Jeong Hoo Lee
article en

Abstract

Background: Catatonia is a neuropsychiatric syndrome involving motor, behavioral, cognitive, and affective dysfunction that is associated with substantial morbidity and mortality. While benzodiazepines and electroconvulsive therapy (ECT) are first-line treatments for catatonia, alternative pharmacologic options are often used when response is inadequate or ECT is unavailable. N-methyl-D-aspartate receptor antagonists, particularly amantadine and memantine, have been used as second-line agents, though evidence remains limited to case reports and small series. Objective: To evaluate the effectiveness of amantadine and memantine in hospitalized adults with catatonia by assessing changes in symptom severity measured by the Bush-Francis Catatonia Rating Scale (BFCRS). We hypothesized that these agents, when used alongside standard treatments, would generate symptom improvement. Methods: A retrospective study of adults hospitalized at Massachusetts General Hospital from 2016 to 2024 was conducted. Patients hospitalized with a diagnosis of catatonia who were treated with memantine or amantadine were identified from clinical records. Catatonia severity was measured using clinically documented BFCRS scores. Pre-post BFCRS changes were analyzed using Wilcoxon signed-rank tests, with planned sensitivity analyses. Results: Fifty-seven patients received amantadine or memantine for catatonia, mostly as adjunctive treatment. One week (±2 days) after initiation, BFCRS total scores decreased by a mean of 4.9 points ( p < 0.001, r = 0.61). Results remained significant when excluding patients who received ECT during the first week of amantadine or memantine treatment ( n = 48; mean change 5.0, p < 0.001) and those with ⩾50% lorazepam-equivalent dose increases ( n = 39; mean change 4.6, p < 0.001). Conclusion: This represents the largest cohort treated with amantadine or memantine for catatonia. Findings suggest significant symptom reduction, supporting their potential role as an adjunctive option. Prospective studies are needed to clarify predictors of response and comparative effectiveness.

Journal of Psychopharmacology
Brigham and Women's Hospital (US), Harvard University (US), Brigham and Women's Faulkner Hospital (US), Massachusetts General Hospital (US), Mass General Brigham (US), University of Pennsylvania (US)
National Institute of Mental Health and Neurosciences
Good health and well-being
Openalex Percentile: Top 12%
Electroconvulsive Therapy Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon